Guangdong Marubi Biotechnology Co
Guangdong Marubi Biotechnology Co., Ltd. engages in the research and development, design, production, sale, and service of various cosmetics in China. The company provides skin care, make up, and eye care products. It offers its products under the Marubi, Lianhuo, Haruji, and the Love Fire brand names. The company was founded in 2002 and is based in Guangzhou, China.
Guangdong Marubi Biotechnology Co (603983) - Total Assets
Latest total assets as of September 2025: CN¥4.85 Billion CNY
Based on the latest financial reports, Guangdong Marubi Biotechnology Co (603983) holds total assets worth CN¥4.85 Billion CNY as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Guangdong Marubi Biotechnology Co - Total Assets Trend (2011–2024)
This chart illustrates how Guangdong Marubi Biotechnology Co’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Guangdong Marubi Biotechnology Co - Asset Composition Analysis
Current Asset Composition (December 2024)
Guangdong Marubi Biotechnology Co's total assets of CN¥4.85 Billion consist of 58.4% current assets and 41.6% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 40.1% |
| Accounts Receivable | CN¥58.00 Million | 1.2% |
| Inventory | CN¥219.66 Million | 4.3% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥699.16 Million | 13.8% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Guangdong Marubi Biotechnology Co's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Guangdong Marubi Biotechnology Co's current assets represent 58.4% of total assets in 2024, a decrease from 74.3% in 2011.
- Cash Position: Cash and equivalents constituted 40.1% of total assets in 2024, down from 60.9% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 13.0% of total assets, an increase from 2.0% in 2011.
- Asset Diversification: The largest asset category is intangible assets at 13.8% of total assets.
Guangdong Marubi Biotechnology Co Competitors by Total Assets
Key competitors of Guangdong Marubi Biotechnology Co based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Lonkey Industrial Co Ltd Guangzhou
SHE:000523
|
China | CN¥3.66 Billion |
|
Taiyen Biotech Co Ltd
TW:1737
|
Taiwan | NT$8.26 Billion |
|
Tianjin Yiyi Hygiene Products Co Ltd
SHE:001206
|
China | CN¥2.20 Billion |
|
Hunan Resun Co Ltd
SHE:001218
|
China | CN¥3.08 Billion |
|
Dencare (Chongqing) Oral Care Co. Ltd. A
SHE:001328
|
China | CN¥1.90 Billion |
|
Qingdao Kingking Applied Chemistry Co Ltd
SHE:002094
|
China | CN¥3.19 Billion |
|
C&S Paper Co Ltd
SHE:002511
|
China | CN¥9.17 Billion |
|
Anhui Deli Household Glass Co Ltd
SHE:002571
|
China | CN¥3.08 Billion |
Guangdong Marubi Biotechnology Co - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Guangdong Marubi Biotechnology Co generates 0.59x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Guangdong Marubi Biotechnology Co generates $6.75 in net profit.
Guangdong Marubi Biotechnology Co - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.81 | 2.68 | 3.41 |
| Quick Ratio | 1.61 | 2.48 | 3.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥1.16 Billion | CN¥ 1.63 Billion | CN¥ 1.90 Billion |
Guangdong Marubi Biotechnology Co - Advanced Valuation Insights
This section examines the relationship between Guangdong Marubi Biotechnology Co's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.76 |
| Latest Market Cap to Assets Ratio | 0.06 |
| Asset Growth Rate (YoY) | 13.7% |
| Total Assets | CN¥5.06 Billion |
| Market Capitalization | $287.97 Million USD |
Valuation Analysis
Below Book Valuation: The market values Guangdong Marubi Biotechnology Co's assets below their book value (0.06 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Guangdong Marubi Biotechnology Co's assets grew by 13.7% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Guangdong Marubi Biotechnology Co (2011–2024)
The table below shows the annual total assets of Guangdong Marubi Biotechnology Co from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥5.06 Billion | +13.67% |
| 2023-12-31 | CN¥4.45 Billion | +8.86% |
| 2022-12-31 | CN¥4.09 Billion | +8.76% |
| 2021-12-31 | CN¥3.76 Billion | -0.88% |
| 2020-12-31 | CN¥3.80 Billion | +10.44% |
| 2019-12-31 | CN¥3.44 Billion | +62.33% |
| 2018-12-31 | CN¥2.12 Billion | +32.06% |
| 2017-12-31 | CN¥1.60 Billion | +8.61% |
| 2016-12-31 | CN¥1.48 Billion | +8.06% |
| 2015-12-31 | CN¥1.37 Billion | +13.63% |
| 2014-12-31 | CN¥1.20 Billion | +27.97% |
| 2013-12-31 | CN¥939.25 Million | +33.29% |
| 2012-12-31 | CN¥704.69 Million | +18.05% |
| 2011-12-31 | CN¥596.96 Million | -- |